Kura Oncology Management
Management criteria checks 3/4
Kura Oncology's CEO is Troy Wilson, appointed in Mar 2015, has a tenure of 9.67 years. total yearly compensation is $5.25M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 0.75% of the company’s shares, worth $6.26M. The average tenure of the management team and the board of directors is 4 years and 9.1 years respectively.
Key information
Troy Wilson
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 12.3% |
| CEO tenure | 9.7yrs |
| CEO ownership | 0.7% |
| Management average tenure | 4yrs |
| Board average tenure | 9.1yrs |
Recent management updates
Recent updates
Kura Oncology: A Contender In The Field Of Precision Medicine
Nov 21Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?
Nov 01
Kura Oncology: The Long Holding Pattern Is Risky
Aug 12Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Jul 12Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
May 08Kura Oncology: Balancing Act Of Promise And Pragmatism
May 07Kura Oncology: Ziftomenib's Path To AML Market Widens
Jan 31Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price
Jan 25Is Kura Oncology (NASDAQ:KURA) A Risky Investment?
Aug 14Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
Apr 04Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?
Jan 31Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans
Oct 10Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating
Jul 13We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth
Jun 26We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Nov 23We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Aug 09Kura Oncology Investor Presentation - Slideshow
May 08What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?
Dec 14
Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
Dec 10Kura Oncology (KURA) Presents At ASH Virtual Investor Event
Dec 08Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate
Dec 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$198m |
| Jun 30 2024 | n/a | n/a | -US$182m |
| Mar 31 2024 | n/a | n/a | -US$168m |
| Dec 31 2023 | US$5m | US$646k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$143m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$137m |
| Dec 31 2022 | US$5m | US$621k | -US$136m |
| Sep 30 2022 | n/a | n/a | -US$135m |
| Jun 30 2022 | n/a | n/a | -US$133m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$9m | US$600k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$124m |
| Jun 30 2021 | n/a | n/a | -US$114m |
| Mar 31 2021 | n/a | n/a | -US$101m |
| Dec 31 2020 | US$4m | US$573k | -US$90m |
| Sep 30 2020 | n/a | n/a | -US$81m |
| Jun 30 2020 | n/a | n/a | -US$74m |
| Mar 31 2020 | n/a | n/a | -US$68m |
| Dec 31 2019 | US$3m | US$542k | -US$63m |
| Sep 30 2019 | n/a | n/a | -US$61m |
| Jun 30 2019 | n/a | n/a | -US$60m |
| Mar 31 2019 | n/a | n/a | -US$60m |
| Dec 31 2018 | US$5m | US$526k | -US$60m |
| Sep 30 2018 | n/a | n/a | -US$55m |
| Jun 30 2018 | n/a | n/a | -US$49m |
| Mar 31 2018 | n/a | n/a | -US$43m |
| Dec 31 2017 | US$2m | US$472k | -US$35m |
Compensation vs Market: Troy's total compensation ($USD5.25M) is above average for companies of similar size in the US market ($USD3.19M).
Compensation vs Earnings: Troy's compensation has been consistent with company performance over the past year.
CEO
Troy Wilson (55 yo)
9.7yrs
Tenure
US$5,251,407
Compensation
Dr. Troy Edward Wilson, Ph D., J.D., is Independent Director of Cartography Biosciences, Inc. from October 2024. He is Co-Founder of Avidity Biosciences Inc. and had been its Executive Chairman since Febru...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.7yrs | US$5.25m | 0.75% $ 6.3m | |
| Chief Operating Officer | 5.3yrs | US$2.16m | 0.016% $ 132.1k | |
| Chief Legal Officer & Corporate Secretary | 3.1yrs | US$1.98m | 0.0069% $ 58.1k | |
| Chief Medical Officer | 4.3yrs | US$2.47m | 0.0039% $ 32.7k | |
| Senior Vice President of Finance & Accounting | 2.8yrs | no data | 0.015% $ 128.2k | |
| Executive Vice President of Investor Relations & Corporate Communications | 7.1yrs | no data | no data | |
| Senior Vice President of Manufacturing & Supply Chain | 4.8yrs | no data | no data | |
| VP and Global Head of Program Leadership & Project Management | 3.7yrs | no data | no data | |
| Executive Vice President of Clinical Development | 2.8yrs | no data | no data | |
| Chief Commercial Officer | 1.3yrs | no data | no data | |
| Senior Vice President of Translational Research | no data | no data | no data |
4.0yrs
Average Tenure
53yo
Average Age
Experienced Management: KURA's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.7yrs | US$5.25m | 0.75% $ 6.3m | |
| Clinical Advisor | no data | no data | no data | |
| Independent Director | 9.1yrs | US$275.69k | 0% $ 0 | |
| Independent Director | 6yrs | US$279.80k | 0% $ 0 | |
| Lead Independent Director | 9.6yrs | US$300.54k | 0.031% $ 259.0k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Chairman of the Scientific Advisory Board | no data | no data | no data | |
| Clinical Advisor | no data | no data | no data | |
| Clinical Advisor | no data | no data | no data | |
| Clinical Advisor | no data | no data | no data | |
| Independent Director | 3.4yrs | US$279.05k | 0% $ 0 |
9.1yrs
Average Tenure
63.5yo
Average Age
Experienced Board: KURA's board of directors are considered experienced (9.1 years average tenure).